Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (6066)	12/3/1998 12:03:00 AM
From: Vector1	Read Replies (2) \| Respond to of 9719

I assume everyone has seen this. Why wasn't the stock up big. Also INCY has a royalty for drugs developed derived from its database. IT is a low single digit royalty which increases if the target is a patented gene or EST. My guess is a 1% royalty goes to 3%. INCY may be the cheapest stock in our porfolio V1 ----------------------------------------------------------- 12/02 6:02A (DJ) +Incyte Pharma, Zeneca In Agrigenomics Alliance >INCY ZEN Story 0899 Incyte - Zeneca -2: Multi-Year Pact To Study Plant Genes>ZEN WILMINGTON, Del. (Dow Jones)--Incyte Pharmaceuticals Inc. (INCY) and Zeneca Group PLC (ZEN) formed a multi-year agrigenomics alliance. Agrigenomics is the detailed study of the genetic make-up of a plant and how all of the genes work together to produce a crop, the companies said. In a press release Wednesday, the companies said Zeneca will have access to Incyte's PhytoSeq database under the collaboration. Incyte will apply its high-throughput gene sequencing and bioinformatics capabilities towards the generation of gene sequence and expression information for crop plants designated by Zeneca to be included in the PhytoSeq database. The PhytoSeq database will contain sequence information from a range of agriculturally important crops, including wheat, maize and rice. Zeneca will also have access to Incyte's microarray technology for the study of gene pathways and to monitor gene expression in plants. Inctye will provide Zeneca with data from both custom and prefabricated microarrays. This will give an unprecedented level of information, allowing Zeneca researchers to study multigenic pathways, or thousands of genes at a time, in a single experiment. The companies said this collaboration extends an existing pharmaceutical arrangement between them, which was initiated in 1996, covering access to